<生产厂家价格>

雷贝拉唑钠

雷贝拉唑钠用途

Rabeprazole (LY307640)钠盐是质子泵抑制剂,可抗溃疡。

雷贝拉唑钠名称

[ CAS 号 ]:
117976-90-6

[ 中文名 ]:
雷贝拉唑钠盐

[ 英文名 ]:
Rabeprazole sodium

[中文别名 ]:

雷贝拉唑钠

[英文别名 ]:

RABEPRAZOLE NA
Pariet
Zechin
Rabonik
Rebeprazole sodium
Aciphex
Rabeprazole Sodium Salt
Rabeprazole sodium
Sodium rabeprazole
Rabeprazole (sodium)

雷贝拉唑钠生物活性

[ 描述 ]:

Rabeprazole (LY307640)钠盐是质子泵抑制剂,可抗溃疡。

[ 相关类别 ]:

信号通路 >> 跨膜转运 >> 质子泵

研究领域 >> 炎症/免疫

[参考文献]

[1]. http://www.drugbank.ca/drugs/DB01129

[相关活性小分子]

雷贝拉唑钠物理化学性质

[ 密度 ]:
0.45~0.55 g/ml

[ 沸点 ]:
603.9ºC at 760 mmHg

[ 熔点 ]:
140-141ºC dec.

[ 分子式 ]:
C₁₈H₂₀N₃NaO₃S

[ 分子量 ]:
381.424

[ 闪点 ]:
319.1ºC

[ 精确质量 ]:
381.112305

[ PSA ]:
93.41000

[ LogP ]:
3.48420

[ 外观性状 ]:
白色或灰白色结晶粉末

[ 储存条件 ]:
Hygroscopic, -20°C Freezer, Under Inert Atmosphere

[ 水溶解性 ]:
H2O: soluble10mg/mL (clear solution)

雷贝拉唑钠MSDS

雷贝拉唑钠安全信息

[ 危险品运输编码 ]:
NONH for all modes of transport

[ 海关编码 ]:
2933399090

雷贝拉唑钠合成路线

雷贝拉唑钠上下游产品

雷贝拉唑钠上游产品

雷贝拉唑钠下游产品

雷贝拉唑钠海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

雷贝拉唑钠文献

Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole.

Life Sci. 110(1) , 35-43, (2014)

First; to develop rabeprazole (RP)-alginate core coated chitosan nanoparticles (NP) utilizing water in oil (W/O) nanoemulsion technique. Second; formulation of transdermal patches loaded RP-NP that av...

Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.

J. Infect. Dis. 208(7) , 1123-30, (2013)

Clarithromycin-resistant Helicobacter pylori is associated with point mutations in the 23S ribosomal RNA (rRNA) gene.A total of 1232 patients participated and were divided into 2 control groups and 1 ...

Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy. Shi S, Wang H, Gao H, et al.

Dig. Dis. Sci. 59(7) , 1398-405, (2014)

更多文献